Blueprint May Corner EGFR Exon Mutated Lung Cancer Market With Lengo Buyout

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Lengo’s preclinical LNG-451, along with Blueprint’s BLU-945 and BLU-701, could create a portfolio of therapies covering 97% of non-small cell lung cancer cases involving EGFR exon mutations.

Doctor examining at lungs radiograph x-ray film of patient in operation room. medical concept.
Blueprint's buyout of Lengo adds a third NSCLC drug candidate

Blueprint Medicines Corporation acquired Lengo Therapeutics, a privately held biotech with an early-stage asset that combined with two of Blueprint’s own pipeline candidates could enable it to address roughly 97% of epidermal growth factor receptor (EGFR) exon mutation-related lung cancer cases. The Cambridge, MA-based firm said on 29 November it has agreed in principle to acquire Lengo for $250m in cash up front plus up to $215m in potential approval and sales-based milestones.

Lengo’s preclinical LNG-451 is an oral precision therapy designed to address non-small cell lung cancer (NSCLC) with EGFR exon 20...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.